Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Primary Immune Thrombocytopenia (ITP)
NCT07019545Phase 2Not yet recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in primary immune thrombocytopenia (ITP), sponsored by Hellenic Society of Hematology. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07019545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019545.